Jupiter Neurosciences Enters License Agreement With PharmAla Biotech For Perpetual Exclusive U.S. Rights To ALA-002; Deal Worth Up To $100M With Milestone Payments

Loading news article.

Jupiter Neurosciences Enters License Agreement With PharmAla Biotech For Perpetual Exclusive U.S. Rights To ALA-002; Deal Worth Up To $100M With Milestone Payments | WAPE

Jupiter Neurosciences Enters License Agreement With PharmAla Biotech For Perpetual Exclusive U.S. Rights To ALA-002; Deal Worth Up To $100M With Milestone Payments

Article summary

Related companies

Comments —